title: Potentiation of aflatoxin B1-induced hepatocarcinogenesis in the rat by pretreatment with buthionine sulfoximine.
abstract: A single i.p. dose of aflatoxin B1 (AFB1) (1.0 and 2.0 mg/kg body wt)-induced hepatocarcinogenesis with phenobarbital as a promoter has been examined in young male Fischer rats. Immunohistochemical method has been employed to detect AFB1-induced glutathione S-transferase placental form (GST-P)-positive hepatic foci observed from 3 week and 10 week to 40-48 week periods. With 2.0 mg AFB1 dosing, the number, area and volume occupied by GST-P-positive hepatic foci increased significantly and progressively from 3 week, 10 week and 48 week periods. In long term studies (40-48 weeks), 1.0 mg and 2.0 mg AFB1 dose levels yielded linear response in area and volume occupied by AFB1-induced hepatic foci. Pretreatment of rats with L-buthionine sulfoximine (BSO), a GSH depleter, at a dose of 4 mmol/kg body wt 4 and 2 h before 1.0 or 2.0 mg AFB1 treatment enhanced the number, area and volume of GST-P-positive hepatic foci, increases being the largest at shorter time periods (3 and 10 weeks) compared to longer time periods (40 and 48 weeks). This report appears to be the first example of an enhanced chemical induced hepatocarcinogenesis in a long term study in any experimental animals species by a GSH depleting agent.
authors.affiliation: Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA 19140, USA.
authors.forename: S
authors.initials: S
authors.lastname: Hiruma
authors.forename: M
authors.initials: M
authors.lastname: Kimura
authors.forename: K
authors.initials: K
authors.lastname: Lehmann
authors.forename: P
authors.initials: P
authors.lastname: Gopalan-Kriczky
authors.forename: G Z
authors.initials: GZ
authors.lastname: Qin
authors.forename: H
authors.initials: H
authors.lastname: Shinozuka
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: P D
authors.initials: PD
authors.lastname: Lotlikar
mesh_terms: D016604:Aflatoxin B1; D000818:Animals; D019328:Buthionine Sulfoximine / Q000494:pharmacology*; D002273:Carcinogens; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005982:Glutathione Transferase / Q000378:metabolism*; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009374:Neoplasms, Experimental / Q000473:pathology; D010634:Phenobarbital; D051381:Rats; D011916:Rats, Inbred F344; D013997:Time Factors
chemical_list: D002273:Carcinogens; D004791:Enzyme Inhibitors; D019328:Buthionine Sulfoximine; D016604:Aflatoxin B1; D005982:Glutathione Transferase; D010634:Phenobarbital